Document Detail

Vancomycin decreases insulin sensitivity and is associated with alterations in intestinal microbiota and bile acid composition in obese subjects with metabolic syndrome.
MedLine Citation:
PMID:  24316517     Owner:  NLM     Status:  Publisher    
BACKGROUND: Obesity has been associated with changes in the composition and function of the intestinal microbiota. Modulation of the microbiota by antibiotics also alters bile acid and glucose metabolism in mice. Hence, we hypothesized that short term administration of oral antibiotics in humans would affect fecal microbiota composition and subsequently bile acid and glucose metabolism.
METHODS: In this single blinded randomized controlled trial, 20 male obese subjects with metabolic syndrome were randomized to 7 days of amoxicillin 500mg t.i.d. or 7 days of vancomycin 500mg t.i.d. At baseline and after 1 week of therapy, fecal microbiota composition (Human Intestinal Tract Chip phylogenetic microarray), fecal and plasma bile acid concentrations as well as insulin sensitivity (hyperinsulinemic euglycemic clamp using [6,6-(2)H2]-glucose tracer) were measured.
RESULTS: Vancomycin reduced fecal microbial diversity with a decrease of gram-positive bacteria (mainly Firmicutes) and a compensatory increase in gram-negative bacteria (mainly Proteobacteria). Concomitantly, vancomycin decreased fecal secondary bile acids with a simultaneous postprandial increase in primary bile acids in plasma (p<0.05). Moreover, changes in fecal bile acid concentrations were predominantly associated with altered Firmicutes. Finally, administration of vancomycin decreased peripheral insulin sensitivity (p<0.05). Amoxicillin did not affect any of these parameters.
CONCLUSIONS: Oral administration of vancomycin significantly impacts host physiology by decreasing intestinal microbiota diversity, bile acid dehydroxylation and peripheral insulin sensitivity in subjects with metabolic syndrome. These data show that intestinal microbiota, particularly of the Firmicutes phylum contributes to bile acid and glucose metabolism in humans. This trial is registered at the Dutch Trial Register (NTR2566).
Anne Vrieze; Carolien Out; Susana Fuentes; Lisanne Jonker; Isaie Reuling; Ruud S Kootte; E van Nood; Frits Holleman; Max Knaapen; Johannes A Romijn; Maarten R Soeters; Ellen E Blaak; Geesje M Dallinga-Thie; Dorien Reijnders; Mariëtte T Ackermans; Mireille J Serlie; Filip K Knop; Jenst J Holst; Claude van der Ley; Ido P Kema; Erwin G Zoetendal; Willem M de Vos; Joost B L Hoekstra; E S Stroes; Albert K Groen; Max Nieuwdorp
Related Documents :
14501607 - Fatty acid composition of serum phospholipid of premenopausal women and postmenopausal ...
634047 - Hydrolysis of biliary phospholipids in the upper small intestine of the chick.
6482177 - Impaired myocardial lipid metabolism in phosphate depletion.
8640347 - Differential effects of fibrates on the acyl composition of microsomal phospholipids in...
2655577 - Effects of inhibitors on aldolase breakdown after its microinjection into hela cells.
11592727 - Conjugated linoleic acid supplementation in humans--metabolic effects.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-12-5
Journal Detail:
Title:  Journal of hepatology     Volume:  -     ISSN:  1600-0641     ISO Abbreviation:  J. Hepatol.     Publication Date:  2013 Dec 
Date Detail:
Created Date:  2013-12-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8503886     Medline TA:  J Hepatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013. Published by Elsevier B.V.
Department of Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Advanced paternal age and mortality of offspring under 5 years of age: a register-based cohort study...
Next Document:  Dietary glycotoxins exacerbate progression of experimental fatty liver disease.